Thomas A. Ullman
Thomas A. Ullman has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Noam Harpaz
Icahn School of Medicine at Mount Sinai Henry D. Janowitz Division of Gastroenterology New York, NY, 10029
11 shared publications - Steven H. Itzkowitz
Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
11 shared publications - Joana Torres
Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
7 shared publications - Jean-Frederic Colombel
The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA
6 shared publications Shailja Shah
6 shared publicationsAsher Kornbluth
5 shared publications
Latest Publications
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-818-818
Mo1832 - Baseline Level of Integrin A4B7 on Circulating Plasmablasts Predicts Response to Vedolizumab in Patients with Inflammatory Bowel Disease
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-818-818
Mo1832 - Baseline Level of Integrin A4B7 on Circulating Plasmablasts Predicts Response to Vedolizumab in Patients with Inflammatory Bowel Disease
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S600-S601
Impact of Real World Home-Based Remote Monitoring on Quality of Care and Quality of Life in IBD Patients: Interim Results of Pragmatic Randomized Trial
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S600-S601
Impact of Real World Home-Based Remote Monitoring on Quality of Care and Quality of Life in IBD Patients: Interim Results of Pragmatic Randomized Trial
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S75-S76
High Rate of Advanced Neoplasia after Detection of Low-Grade Dysplasia in Inflammatory Bowel Disease Patients with Primary Sclerosing Cholangitis
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S75-S76
High Rate of Advanced Neoplasia after Detection of Low-Grade Dysplasia in Inflammatory Bowel Disease Patients with Primary Sclerosing Cholangitis
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S371
High Risk of Pouch Dysplasia in IBD-PSC Patients Following Total Proctocolectomy
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S371
High Risk of Pouch Dysplasia in IBD-PSC Patients Following Total Proctocolectomy
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S585
Su1907 Exploring MEChanisms of IBD traNsmission In Utero through the Microbiome: The MECONIUM Study Pilot
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S585
Su1907 Exploring MEChanisms of IBD traNsmission In Utero through the Microbiome: The MECONIUM Study Pilot
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S573
Su1862 Prevalence of Advanced Colorectal Neoplasia in Patients With Inflammatory Bowel Disease (IBD) Colitis Undergoing Colectomy in the Modern Era
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S573
Su1862 Prevalence of Advanced Colorectal Neoplasia in Patients With Inflammatory Bowel Disease (IBD) Colitis Undergoing Colectomy in the Modern Era
- Open Access
- 1 May 2013
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (9) , 1827-1832
High Rates of Metachronous Colon Cancer or Dysplasia After Segmental Resection or Subtotal Colectomy in Crohnʼs Colitis
In ulcerative colitis, total proctocolectomy is the treatment of choice for patients with colonic dysplasia or cancer because of the high risk for metachronous neoplasia. It is unknown whether patients with Crohn's disease and colon cancer or dysplasia have a similar risk. We retrospectively reviewed the charts of 75 patients treated at our center from 2001 to 2011 with Crohn's disease and colon cancer who underwent segmental resection or subtotal colectomy (STC). We then identified the presence or absence of subsequent colon cancer or dysplasia in these patients during the follow-up (0–19 years). Of the 64 patients with colon cancer, 25 had at least 1 metachronous cancer (39%). The mean time to a new cancer was 6.8 years. Eighty-five percent of patients (21/25) were undergoing annual screening colonoscopy. Of the 11 patients with dysplasia, 5 (46%) had a new dysplasia. Mean time to a new dysplastic lesion was 5.0 years. Nineteen of the 47 patients (40%) who had a segmental resection for colon cancer developed metachronous cancer and 6/17 patients (35%) with a STC had metachronous cancer. Two of the 4 patients (50%) with STC for dysplasia (50%) had a new dysplasia and 3/7 patients (43%) with segmental resection had a new dysplasia. There was no significant difference (P = 0.61) between recurrence rates in patients with segmental resection versus STC. The high rate of metachronous colon cancer after surgical resection suggests that total proctocolectomy should be considered. Larger studies are required to determine if the same is true for dysplasia.
- 1 May 2013
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (9) , 1827-1832
Open AccessHigh Rates of Metachronous Colon Cancer or Dysplasia After Segmental Resection or Subtotal Colectomy in Crohnʼs Colitis
In ulcerative colitis, total proctocolectomy is the treatment of choice for patients with colonic dysplasia or cancer because of the high risk for metachronous neoplasia. It is unknown whether patients with Crohn's disease and colon cancer or dysplasia have a similar risk. We retrospectively reviewed the charts of 75 patients treated at our center from 2001 to 2011 with Crohn's disease and colon cancer who underwent segmental resection or subtotal colectomy (STC). We then identified the presence or absence of subsequent colon cancer or dysplasia in these patients during the follow-up (0–19 years). Of the 64 patients with colon cancer, 25 had at least 1 metachronous cancer (39%). The mean time to a new cancer was 6.8 years. Eighty-five percent of patients (21/25) were undergoing annual screening colonoscopy. Of the 11 patients with dysplasia, 5 (46%) had a new dysplasia. Mean time to a new dysplastic lesion was 5.0 years. Nineteen of the 47 patients (40%) who had a segmental resection for colon cancer developed metachronous cancer and 6/17 patients (35%) with a STC had metachronous cancer. Two of the 4 patients (50%) with STC for dysplasia (50%) had a new dysplasia and 3/7 patients (43%) with segmental resection had a new dysplasia. There was no significant difference (P = 0.61) between recurrence rates in patients with segmental resection versus STC. The high rate of metachronous colon cancer after surgical resection suggests that total proctocolectomy should be considered. Larger studies are required to determine if the same is true for dysplasia.